Status:
UNKNOWN
Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
Swiss National Science Foundation
Conditions:
Intracranial Embolism
Thrombosis
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The purpose of the present, randomized, controlled multicenter phase III trial is to investigate the safety and efficacy of continuous 1-hour insonation of occluded middle cerebral artery with 2 MHz T...
Detailed Description
Thrombolysis with intravenous(iv) tissue plasminogen activator (t-PA) is the only effective and approved therapy for acute ischemic stroke. The most frequent cause of ischemic stroke is thrombosis of ...
Eligibility Criteria
Inclusion
- acute ischemic stroke in the MCA territory according to clinical and cranial computed tomography (CT) or cranial MR imaging (MRI) findings
- patient undergoing iv thrombolysis with t-PA within 3 hours after stroke onset
- Occlusion of sphenoidal (M1) or insular (M2) segment of the MCA at CT (CTA), MR (MRA) or catheter (CA) angiography
- appropriate temporal bony window without echocontrast agents for insonation with TCCS
- full functional independence prior to present stroke (mRS 0-1), use of a cane for walking due to comorbid condition is acceptable
- written informed consent, signed and dated by the subject (or subject's authorized representative, if allowed by local laws) and by the person obtaining the consent, indicating agreement to comply with all protocol-specific procedures
Exclusion
- unconsciousness (more than 2 points on item 1a on NIHSS)
- history of intracranial hemorrhage, arteriovenous malformation or aneurysm
- severe cranio-cerebral trauma within the last 3 months
- symptoms of subarachnoidal hemorrhage
- time of symptom onset unclear
- large surgical intervention or trauma within the last 10 days
- expected survival below 90 days after iv t-PA treatment
- severe hepatic disease, esophageal varices, acute pancreatitis
- septic embolism, endocarditis, pericarditis after myocardial infarction
- pregnancy or childbirth within the last 30 days or nursing mothers
- history of hemorrhagic diathesis or coagulopathy
- untreatable increase of arterial blood pressure (\>185mmHg systolic, \>110mmHg diastolic)
- intracranial hemorrhage, arteriovenous malformations or aneurysm at brain imaging
- thrombocytes \<100'000 per microliter
- international normalized ratio (INR)\>1.7 or partial thromboplastin time (PTT) prolongated
- serum glucose \<2.7mmol/l or \>22.2mmol/l
- severe renal insufficiency or other contraindications against CT-contrast agents
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
June 1 2009
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00336596
Start Date
June 1 2006
End Date
June 1 2009
Last Update
April 27 2007
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Kantonsspital Aarau, Department of Neurology
Aarau, Switzerland
2
University Hospital of Basel, Department of Neurology
Basel, Switzerland
3
University hospital of Bern, Department of Neurology
Bern, Switzerland
4
University Hospital of Geneva, Department of Neurology
Geneva, Switzerland